Alira Health

Alira Health
Contact us
Alira Health
Menu

ISPOR Europe

November 17 - 20, 2024 | Barcelona, Spain

We are pleased to announce that we will attend, sponsor and present posters at ISPOR Europe, the leading global conference in Europe for health economics and outcomes research (HEOR).

At Alira Health, our expert team offers strategic consulting in access, evidence generation, pricing strategies and management to maximize your commercial success. We can support you from early stages of your product development through value communication, including HEOR, real-world evidence, and go-to-market strategies.

We are also excited to invite all ISPOR Europe delegates to attend the “Women in HEOR” reception sponsored by Alira Health. The reception will take place on November 19. Join us for networking and collaboration with fellow professionals who share your passion for advancing women’s roles in HEOR.

Want to meet at ISPOR Europe? Contact us to set up a meeting. 
Contact us to set up a meeting

Attend Our Poster Presentations

During the conference our team will be presenting the high number of 16 posters. We are proud that the poster “Assessing the Value of Real-World Evidence for HTA-Decision Making” has been selected as Top 5% Finalists for the ISPOR 2024 Research Presentation Awards. Check below to discover all our posters and their presentation times. Make sure you do not miss them!

Methods to Include the Organizational Impacts in Health-Economic Evaluations: Experience From CAR-T in France

Authors
Fernandes Soares, J; Pozzar, M; Autin, E; Couillerot, A-L

Date and time
Monday, November 18
12:30 – 13:30

Epidemiology, Survival, and Healthcare Resource Use of Patients With Pulmonary Hypertension Associated With Lung Disease and/or Hypoxia in the UK

Authors
Kiely, D.G; Wort, S.J; Funes, D.F; Petrica, N; Proenca, C; Pini, M; Fernández Delgado, M; Bacchini Jeanneret, G.

Date and time
Monday, November 18
12:30 – 13:30 

Incremental Burden Attributable to Exposure to Socio-Environmental Factors on Patients With Lung Cancer in France

Authors
Youinou, M; Rosé, M; Sano, B; Ricci, JF; Petrica, N. 

Date and time
Monday, November 18
12:30 – 13:30

Budget Impact Analysis of Ublituximab as a Maintenance Treatment for Relapsing Multiple Sclerosis (RMS) in Spain

Authors
Le Rouzo, G; Conde Galán, C;Hernaez-Colque, M; Aguado, M; Castillo, C

Date and time
Monday, November 18
18:00 – 19:00

Integrated Care Process and Pharmacological Prescription for Patients With Hypercholesterolemia or Mixed Dyslipidemia at High or Very High Cardiovascular Risk in Catalonia

Authors
Guiu Segura, JM; García, V;
De la Paz, I; Hernaez-Colque, M; Miralles, M; Marzo, I; Salvador, N; Carod, C; Zamora, A; Yago, G

Date and time
Tuesday, November 19
10:30 – 13:30

Cost-Effectiveness Analysis of Difelikefalin for the Treatment of Chronic Kidney Disease Associated-Pruritus (CKD-aP) in Spain

Authors
Sánchez-Álvarez, E; Poveda, JL; Sánchez-Villanueva, R; De la Paz Cañizares, I; Hernaez Colque, M;
Ramirez de Arellano, A; Ruiz-Andrés, O

Date and time
Tuesday, November 19
10:30 – 13:30 

Characterization of Trabeculectomy Use and the Impact of COVID-19 in Medicare Beneficiaries With Primary Glaucoma by US Region

Authors
Nair, A; Buser, H; Gowda, M; Delise, B; Ricci JF

Date and time
Tuesday, November 19
12:30 – 13:30 

Typology of Patients With Lung Cancer According to Demographics and Exposure to Environmental Factors in France: A Real-World Study

Authors
Youinou, M; Rosé, M; Sano, B; Ricci, JF; Petrica, N

Date and time
Tuesday, November 19
12:30 – 13:30 

Epidemiology and Hospital Management of Patients With PROS in France

Authors
Canaud, G; Sano, B; Beziz, D; Petrica, N; Benkanoun, L; Pouriel, M; Moutie, AS; Couray-Targe, S

Date and time
Tuesday, November 19
12:30 – 13:30 

Top 5% Finalists for the ISPOR 2024 Research Presentation Awards
Assessing the Value of Real-World Evidence for HTA-Decision Making

Authors
Angeli, E; Sabbar, W; Badinedi, R; Godbole, M; Nascimento, J; Proenca, C

Date and time
Tuesday, November 19
16:00 – 16:45

Understanding the Pricing and Reimbursement Outcomes of Advanced Therapy Medicinal Products (ATMP) in Spain

Authors
Vico, T; Águila, M; Hernaez, M; De la Paz, I; Castillo, C

Date and time
Tuesday, Novembre 19
18:00 – 19:00

Global Dynamics of Drug Pricing: Analyzing the Influence of Emerging Countries on Pricing Strategies in Developed Nations 

Authors
Bordoy, C; Zhu, XW; Stasse, C; Vidiella, E; Lizano, I; Blanqué, N

Date and time
Tuesday, November 19
18:00 – 19:00 

Patient Motivations, Concerns, and Perspectives on Sharing Their Electronic Medical Records (EMRs) Using Digital Health Applications: A Preliminary Study

Authors
George, F; Willmon, R; Perez-Guagnelli, E; Ricci, JF

Date and time
Tuesday, November 19
18:00 – 19:00

Economic Evaluation of the Organizational Impact of Atezolizumab Subcutaneous in French Hospitals

Authors
Fernandes Soares, J; Pozzar, M; Autin, E; de Lehvenfehlt, A; Bachelot, M; Gherardi, A; Cormier, N

Date and time
Wednesday, November 20
9:00 – 10:00 

Adaptation and Validation of a Bidirectional Matching Algorithm to Enrich Hospital Data With Information From the French National Death Registry: A Case Study in Patients With Lung or Prostate Cancer (MO-REAL)

Authors
Sanchez, S; Lehmann, E; Corneloup Savignol, H; Baradji, A; Ricci, JF; Nogues,R; Waegeneire, C; Barbara, L

Date and time
Wednesday, November 20
9:00 – 10:00

Development of Patient-Centric Digital Engagement Methods to Address Low Adoption and Adherence to Digital Health Tools: A Novel Conceptual Framework 

Authors
Doherty, J; Willmon, R; Perez-Guagnelli, E; Ricci, JF 

Date and time
Wednesday, November 20
9:00 – 10:00

Meet Our Delegates

Sandra Walsh
Consultant 

Ahmad Bechara

Ahmad Bechara
Executive Vice President,
Global Pharma

Nerea Blanqué-Catalina
Partner,
Market Access and Pricing

Chus Castillo
Partner,
Market Access and Pricing

Andrea Mantovani

Andrea Mantovani
Partner,
Market Access and Pricing

Albert Canela-square

Albert Canela
Partner,
Market Access and Pricing

Anne-line Couillerot

Anne-Line Couillerot
Principal,
HEOR Access France

Marc Manau
Principal,
Market Access and Pricing 

Ariadna Castillo

Ariadna Castillo
Principal,
Market Access and Pricing

Gilberto Bento

Gilberto Bento
Engagement Manager,
Market Access and Pricing

Isabel de la Paz
Engagement Manager,
Market Access and Pricing

Aina Pi

Aina Pi
Engagement Manager,
Market Access and Pricing

Irene Lizano

Irene Lizano
Engagement Manager, Market Access and Pricing

Jornt Mos
Consultant,
Market Access and Pricing

Clara Bordoy
Senior Consultant,
Market Access and Pricing

Tania Vico
Consultant,
Market Access and Pricing

Irene Asensio

Irene Asensio
Consultant,
Market Access and Pricing

Mario Pozzar

Mario Pozzar
Consultant,
HEOR Access France

Sarah Sadeuk

Sarah Sadeuk-Benabbas
Consultant,
HEOR Access France

Eduardo Pérez

Eduardo Pérez
Engagement Manager,
Patient Engagement

Mathieu Rose

Mathieu Rosé
Director,
Real-World Solutions

Nicoleta Petrica

Nicoleta Petrica
Associate Director,
Real-World Solutions

Elodie Lehmann
Associate Director, Real-World Solutions

Tiago Matos
Associate Director,
Global HEOR

Aurelie Chekroun Martinot

Aurélie Chekroun Martinot
Associate Director,
Real-World Solutions

Erwan Autin
Engagement Manager,
HEOR Access France

Madhusubramanian Muthukumar
Senior Consultant,
Real-World Solutions

Warda Sabbar
Consultant,
HEOR Access France

Batourou Sano
Consultant,
Real-World Solutions

Aaksa Nair

Aaksa Nair
Consultant

Amaia Zurinaga
Associate Consultant,
Real-World Solutions

Batourou Sano
Consultant,
Real-World Solutions

Aaksa Nair

Aaksa Nair
Consultant

Check Out Our Recent Publications

Article

The Role of Real-World Data in the Development of Lupus Solutions

This article explores the benefits of RWD in lupus, the value of leveraging RWD throughout the lupus product lifecycle, and the RWD sources available in this indication.

Learn more

White Paper

Advanced Therapies Medicinal Products: Access, Pricing, and Ethical Issues in Perspective

Download this white paper to learn about challenges in access and commercialization of ATMPs and future innovative solutions for ATMPs access.

Learn more

Article

WHO Model Lists of Essential Medicines: What You Need to Know 

Our Market Access experts share the importance of the EML for pharma companies and four best practices for a successful application, based on our extensive experience in WHO interactions.

Learn more 

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.